NPR interviews Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation, about the Foundation’s sale of royalty rights to CF treatments and what the expanded resources mean
The CF Foundation and Vertex have had tremendous success in moving the Vertex drugs, VX-809 and VX-661 forward. These drugs have been developed to correct the most common mutation, Delta
The CF Foundation announced a $15 million research initiative with biopharmaceutical company Shire to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
Dear Friend, I have exciting news to share with you about a transformational moment in our shared journey to cure cystic fibrosis. Today, we announced that our drug development affiliate,